Fimasartan, a novel angiotensin II receptor antagonist

Archives of Pharmacal Research

Volumn 35, Issue 7, 2012, Pages 1123-1126

  Kim, Je Hak ^a   Lee, Joo Han ^a   Paik, Soo Heui ^a   Kim, Ji Han ^a   Chi, Yong Ha ^a  

^a Boryung Pharm Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; CANDESARTAN; FIMASARTAN; LOSARTAN;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEADACHE; HUMAN; IC 50; NAUSEA; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY; URINARY EXCRETION; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PATIENT SAFETY; PYRIMIDINES; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84864912078     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0700-z     Document Type: Article

References (9)

1. Antonaccio, M. J. and Wright, J. J., Enzyme inhibitors of the renin-angiotensin system. Prog. Drug Res., 31, 161-191 (1987). (Pubitemid 18031072)
2. Burnier, M., Angiotensin II type 1 receptor blockers. Circulation, 103, 904-912 (2001). (Pubitemid 32163892)
3. Chi, Y. H., Lee, H., Paik, S. H., Lee, J. H., Yoo, B. W., Kim, J. H., Than, H. K., and Kim, S. L., Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am. J. Cardiovasc. Drugs. 11, 335-346 (2011).
4. Kim, T. W., Yoo, B. W., Lee, J. K., Kim, J. H., Lee, K. T., Chi, Y. H., and Lee, J. Y., Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg. Med. Chem. Lett., 22, 1649-1654 (2012).
5. KNHNES. The First-year Report of the Fifth Korea National Health and Nutrition Examination Surveys (2011).
6. Lee, H., Yang, H. M., Lee, H. Y., Kim, J. J., Choi, D. J., Seung, K. B., Jeon, E. S., Ha, J. W., Rim, S. J., Park, J. B., Shin, J. H., and Oh, B. H., Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in korean patients with hypertension: Findings from two phase II, randomized, double-blind, placebo-controlled studies. Clin. Ther., 34, 1273-1289 (2012a).
7. Lee, S. E., Kim, Y. J., Lee, H. Y., Yang, H. M., Park, C. G., Kim, J. J., Kim, S. K., Rhee, M. Y., and Oh, B. H., Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, doubleblind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin. Ther., 34, 552-568 (2012b).
8. Volpe, M. and Savoia, C., New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integr. Blood Press. Control, 5, 19-25 (2012).
9. Wood, S. M., Mann, R. D., and Rawlins, M. D., Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br. Med. J., 294, 91-92 (1987). (Pubitemid 17230090)